Functional constipation: evidence-based management in AU general practice

What constipation is — and what it is not

Constipation means different things to different patients. To a clinician it is a symptom complex involving difficult, infrequent, or incomplete defaecation. To a patient it might mean straining, hard stools, a feeling of incomplete emptying, or simply not going as often as expected. Most Australian adults assume daily bowel motions are normal — in fact, normal bowel frequency spans three times per day to three times per week.

Functional constipation is constipation arising from disordered gut function rather than structural disease (colorectal cancer, stricture, inflammatory bowel disease) or a systemic metabolic cause (hypothyroidism, hypercalcaemia, diabetes-related autonomic neuropathy). It is common: approximately 14% of Australian adults meet diagnostic criteria, rising to around 30% in people aged over 65 and up to 50% in residential aged care settings, per Gastroenterological Society of Australia (GESA). Women are affected about twice as often as men.

The clinical task in general practice is three-fold: confirm the diagnosis using validated criteria, exclude red flags that warrant investigation, and deliver treatment aligned to guideline recommendations and the clinical subtype. Most cases are manageable without specialist referral.

A. Core clinical — the AU general-practice framework

History

A thorough history defines both the pattern and the likely subtype.

Bowel habit detail — frequency, consistency (Bristol Stool Chart types 1–2 indicate hard stools), degree of straining, sensation of incomplete evacuation, whether manual manoeuvres are required (digital evacuation, perineal splinting), and any episodes of faecal incontinence suggesting overflow.

Onset and duration — functional constipation requires symptom onset ≥6 months prior with active criteria ≥3 months. New onset in a middle-aged or older adult — particularly from age 45 onward — demands attention.

Diet and fluid — fibre intake (a clinically useful question: “How many serves of vegetables and fruit per day?”), total fluid intake, and patterns around meals.

Drug review — constipation is a common medication adverse effect. Key culprits include opioid analgesics (the most potent cause), calcium channel blockers (especially verapamil), anticholinergic drugs (tricyclic antidepressants, antipsychotics, oxybutynin, solifenacin), iron supplements, calcium supplements, aluminium-containing antacids, and diuretics causing relative dehydration.

Pelvic floor symptoms — manual manoeuvres, perineal splinting, and a sensation of anorectal obstruction point toward a defecatory disorder (pelvic floor dyssynergia) rather than simple slow-transit constipation.

Systemic symptoms — cold intolerance, fatigue, or weight gain suggest hypothyroidism; polydipsia and polyuria suggest hypercalcaemia or diabetes.

Alarm features — rectal bleeding, unexplained weight loss, iron-deficiency anaemia, family history of colorectal cancer or IBD, persistent abdominal pain, or significant change in a previously stable bowel pattern all require investigation.

Examination

Abdominal examination looks for distension, mass, or faecal loading. A digital rectal examination (DRE) is essential in any patient with constipation warranting workup: it assesses anal tone, detects faecaloma, fissure, or mass, and — with the patient bearing down — reveals paradoxical contraction of the pelvic floor (the hallmark of defecatory disorder). Neurological examination is appropriate when spinal cord pathology is a consideration (saddle anaesthesia, lower limb signs, urinary retention).

Investigations

Most patients with typical functional constipation and no alarm features require no investigation beyond clinical assessment and DRE. When indicated, per MBS Online:

Targeted bloods: TSH for hypothyroidism; calcium for hypercalcaemia; HbA1c for diabetes; FBC and iron studies if anaemia or rectal bleeding is present; coeliac TTG-IgA if coeliac disease is in the differential; faecal calprotectin if IBD is suspected.

Colonoscopy — reserved for alarm features (rectal bleeding, weight loss, iron deficiency, family history of colorectal cancer) or as part of the NBCSP pathway following a positive FIT result.

Specialist-initiated investigations — colonic transit study using radiopaque markers to confirm slow-transit; anorectal manometry, balloon expulsion test, and defecography to confirm defecatory disorder. These are gastroenterology-referred.

B. Rome IV criteria and subtype classification

Rome IV functional constipation criteria

Therapeutic Guidelines and GESA use Rome IV. The criteria require:

Two or more of six features on ≥25% of defaecations:

1. Straining
2. Lumpy or hard stools (Bristol types 1–2)
3. Sensation of incomplete evacuation
4. Sensation of anorectal obstruction or blockage
5. Manual manoeuvres required (digital evacuation, perineal support)
6. Fewer than three spontaneous complete bowel movements per week

Plus: loose stools rarely present without laxatives; insufficient criteria for irritable bowel syndrome — IBS-C is defined by recurrent abdominal pain associated with defaecation, which is absent in pure functional constipation.

Duration: criteria met for the last three months, with symptom onset ≥6 months before diagnosis.

Subtypes

Normal-transit constipation is the most common subtype. Colonic transit time is measurably normal; patients perceive constipation despite adequate frequency. Responds well to lifestyle modification and osmotic laxatives.

Slow-transit constipation involves reduced colonic propulsive contractions. Patients typically have an infrequent or absent urge to defaecate, marked straining, and poor response to dietary fibre alone. Transit study using radiopaque markers (Sitz markers, plain abdominal X-ray at day 5) confirms delayed transit. Requires more aggressive laxative therapy; refractory cases may need specialist consideration of prucalopride or linaclotide.

Defecatory disorder (anismus / pelvic dyssynergia) occurs when the pelvic floor and external anal sphincter paradoxically contract rather than relax during defaecation. Patients describe a sensation of obstruction, manual manoeuvres, and incomplete evacuation. DRE typically reveals failure of the puborectalis to relax with straining. Confirmed by anorectal manometry and balloon expulsion test. Treatment of choice is pelvic floor physiotherapy and biofeedback through a continence-accredited physiotherapist, with response rates exceeding 70% in randomised controlled trials.

Overlap with IBS-C — when abdominal pain is the dominant symptom and is relieved by or associated with defaecation, the diagnosis shifts to IBS-C and management extends to dietary strategies (low-FODMAP under dietitian supervision) and treatments targeting both pain and motility.

C. Pharmacotherapy — the laxative evidence

Per Therapeutic Guidelines and AMH, the treatment hierarchy is as follows.

Lifestyle foundation — always first

Increase fibre gradually to 25–30 g per day (soluble fibre such as psyllium is preferred when IBS-C overlaps; insoluble wheat bran can worsen symptoms). Fluid intake of 1.5–2 L per day. At least 30 minutes of daily physical activity. Regular post-meal toileting exploiting the gastrocolic reflex. A squat-position footstool (Squatty Potty or equivalent) straightens the anorectal angle and facilitates evacuation. A bowel diary helps track patterns.

Lifestyle modification alone is insufficient for established slow-transit or defecatory disorder subtypes. Combine with pharmacotherapy from the outset in these cases.

First-line: osmotic laxatives

Polyethylene glycol (PEG) — sold as Movicol or OsmoLax — is the preferred first-line agent. A 2010 Cochrane review comparing PEG with lactulose confirmed PEG produces superior stool frequency and consistency with less flatulence. Standard dose is one to two sachets per day, adjusted for response. Safe in older adults, in renal impairment (at standard doses), and in pregnancy.

Lactulose (15–30 mL twice daily) is a non-absorbable disaccharide osmotic laxative. Effective but causes more flatulence and bloating than PEG. The sweet taste makes it acceptable for some patients; exercise caution in diabetes given carbohydrate content.

Magnesium salts (magnesium hydroxide, magnesium oxide) are effective osmotic agents. Avoid in significant renal impairment due to magnesium accumulation risk.

Bulk-forming agents

Psyllium (Metamucil), ispaghula, and sterculia are appropriate for normal-transit constipation only, taken with at least 250 mL of water per dose. Avoid in slow-transit constipation or opioid-induced constipation — without adequate propulsive colonic motility, bulk agents can worsen symptoms or precipitate faecal impaction.

Second-line: stimulant laxatives

Senna (8.6–17.2 mg at night) and bisacodyl (5–15 mg at night) stimulate colonic motility through enteric nerve activation. The historical concern about long-term stimulant laxative use — so-called “cathartic colon” — was systematically addressed by Müller-Lissner et al. (2005), who found no evidence of structural colonic damage or true pharmacological dependence at standard therapeutic doses. Stimulant laxatives are appropriate for long-term use and useful as needed in combination with osmotic agents.

Sodium picosulfate (5–10 mg at night) is an alternative stimulant that is activated in the colon by bacterial enzymes.

Specialist-initiated agents (PBS Authority Required)

Prucalopride (Resolor) is a selective serotonin 5-HT₄ receptor agonist that stimulates high-amplitude colonic propulsive contractions. Available via PBS Authority for chronic severe constipation refractory to at least two standard laxative classes. Dose: 1–2 mg daily (1 mg in significant renal impairment). Generally well tolerated; mild headache on initiation is self-limiting.

Linaclotide (Constella) is a guanylate cyclase-C agonist that increases intestinal fluid secretion and accelerates transit. PBS Authority for chronic idiopathic constipation meeting specific criteria. Taken as 290 mcg once daily, 30 minutes before the first meal. Diarrhoea is the main adverse effect; dose reduction or withholding resolves this.

PAMORAs for opioid-induced constipation — naloxegol (Movantik, 25 mg daily) and subcutaneous methylnaltrexone (Relistor) peripherally reverse opioid gut receptor activation without crossing the blood-brain barrier and thus without reversing central analgesia. Available via PBS Authority for opioid-induced constipation refractory to standard laxatives.

Suppositories and enemas

Glycerin suppositories and bisacodyl suppositories assist evacuation when oral laxatives are insufficient or when rapid effect is needed. Sodium phosphate enemas (Fleet) are effective for disimpaction but require caution in renal impairment and heart failure.

D. Australian operations — MBS, PBS, and NBCSP

MBS billing

Standard GP consultation items via MBS Online cover constipation assessment and management. When constipation arises in the context of multimorbidity — opioid-dependent pain, Parkinson’s disease, spinal cord injury, or frailty — Chronic Disease Management items enable allied health referral. This supports dietitian input for fibre optimisation and referral to a pelvic floor physiotherapist via the Continence Foundation of Australia or a continence-accredited practitioner.

The Health Assessment for people aged 75 and over and the Aboriginal and Torres Strait Islander Health Assessment both include bowel habit review; constipation is a high-yield finding in both older adults and First Nations patients, particularly those in residential care settings.

National Bowel Cancer Screening Programme

From 1 July 2024, the NBCSP provides a free FIT kit every two years to all Australians aged 45–74 (expanded from the previous 50–74 age range). A patient presenting with change in bowel habit should be asked whether they have completed their most recent NBCSP FIT. A positive FIT result requires colonoscopy referral within 120 days. General practice plays a central role in recall, safety-netting, and encouraging participation — particularly in communities with historically lower uptake.

PBS laxative access

Most laxatives — PEG, lactulose, senna, bisacodyl, psyllium, magnesium hydroxide, docusate — are available on general schedule or over the counter without PBS Authority. Prucalopride, linaclotide, naloxegol, and methylnaltrexone require PBS Authority; current criteria are on PBS Online.

E. Special populations

Older adults — constipation prevalence rises with age due to reduced mobility, polypharmacy (particularly opioids, calcium channel blockers, and anticholinergics), reduced fluid intake, and altered rectal sensation. Faecal impaction with overflow incontinence can mimic diarrhoea and is missed if not considered. PEG is safe and effective in older adults. Avoid bulk-forming agents alone in immobile patients. Document bowel charting in residential aged care settings per Australian Commission on Safety and Quality in Health Care standards.

Pregnancy — constipation is common due to progesterone-mediated reduction in colonic motility and mechanical effects of the growing uterus. Lifestyle first. Psyllium, lactulose, and PEG are safe. Short-term senna or bisacodyl is acceptable; avoid mineral oil (risk of lipid aspiration pneumonia and fat-soluble vitamin malabsorption). Avoid enemas in late pregnancy.

Opioid-prescribed patients — document laxative co-prescription alongside any opioid initiation. PEG with a stimulant laxative is the standard combination. If refractory, a PAMORA is indicated per PBS criteria. Reduce opioid dose through multimodal pain management wherever clinically feasible.

Pelvic floor dysfunction post-childbirth — obstetric trauma, perineal tears, and instrumental delivery are risk factors for defecatory disorder and faecal incontinence. DRE is important; refer to a Continence Foundation of Australia accredited physiotherapist.

Children — constipation in children involves distinct behavioural, dietary, and developmental considerations. PEG is first-line; address withholding behaviour early. This article covers adult management; paediatric management follows separate guidelines and is outside its scope.

When to escalate

Escalate or refer when:

• Alarm features are present — arrange colonoscopy or cancer pathway referral promptly
• Refractory constipation does not respond to optimised laxative combination (PEG plus stimulant plus lifestyle over 8–12 weeks)
• Slow-transit constipation is suspected — refer gastroenterology for transit study and consideration of prucalopride or linaclotide
• Defecatory disorder is suspected — manual manoeuvres, obstruction sensation, or DRE showing dyssynergia — refer pelvic floor physiotherapy
• Opioid-induced constipation refractory to PEG plus stimulant — discuss PAMORA, request review of opioid dose
• Faecal impaction with overflow — may require manual or enema disimpaction initially, then sustained laxative regimen
• Pregnancy with severe or refractory constipation — obstetric input

What this article is and is not

This is general health information drawn from current Australian general practice guidelines — Therapeutic Guidelines, AMH, GESA, and Continence Foundation of Australia — and published evidence. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about investigation, specific laxative choice, and referral thresholds are made with your own GP and treating clinicians.

For Australian consumer-friendly information: HealthDirect — Constipation, Better Health Channel — Constipation, Continence Foundation of Australia.

---

Sources cited

1. Therapeutic Guidelines (eTG) — Gastrointestinal: Constipation
2. Australian Medicines Handbook
3. Gastroenterological Society of Australia (GESA)
4. National Bowel Cancer Screening Programme
5. Continence Foundation of Australia
6. HealthDirect — Constipation
7. Better Health Channel — Constipation
8. Australian Commission on Safety and Quality in Health Care
9. Müller-Lissner et al. — Stimulant laxative long-term safety (2005)
10. Cochrane — Osmotic and stimulant laxatives for functional constipation (2010)
11. MBS Online
12. PBS Online